Stage III Follow Up

After treatment, patients with Stage III melanoma should receive a physical examination, including a skin examination, and possibly regular chest x-rays, CT scans of the trunk and pelvis, and brain MRI. The following schedule is recommended:

Type of Follow-up Description

Skin Examination

Annually by healthcare provider
Monthly self-examination

Physical Examination

Years 1-2: every 3-6 months
Years 3-5: every 3-12 months
After Year 5: annually as needed
Monthly self-examination of lymph nodes

Imaging Tests

Possibly every 3-12 months to check for recurrence

Brain MRI

Possibly each year

All patients with Stage III melanoma should have a skin examination once a year for life. Patients should have a physical examination every 3-6 months for years 1-2, every 3-12 months for years 3-5, and then once a year as needed.

Imaging tests are recommended if specific signs of cancer appear. You may also receive imaging tests every 3-12 months to check for cancer recurrence that isn’t causing symptoms. Possible tests for screening include a chest x-ray, CT scan, and a PET/CT scan; and a brain MRI every year. These tests may be done for up to 5 years after treatment has ended. Imaging tests are not recommended after 5 years if there has been no recurrence and you don’t have symptoms.

With treatment, Stage III melanoma is considered intermediate- to high-risk for local recurrence or distant metastasis.

Therefore, early detection of melanoma through skin self- examination and medical examination continues to be of utmost importance.

Large scale studies have shown the following probabilities of disease-free survival:

Survival Rates

5 years after treatment 1 10 years after treatment1

Stage IIIA: 78%

Stage IIIA: 68%

Stage IIIB: 59%

Stage IIIB: 43%

Stage IIIC: 40%

Stage IIIC: 24%


1. American Cancer Society 2011

It is important to get a second opinion

Find a Melanoma Specialist

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.